---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-002761"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-05-18T12:33:17+00:00"
generated_at: "2026-05-18T12:35:42.540071+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics Q1 net loss $2.7M; cash $2.4M; Phase 2/3 trial on track for Q2 2026

## Summary
- Net loss of $2.7M for Q1 2026 vs $1.7M in Q1 2025; R&D expenses rose 133% to $1.4M driven by trial preparation.
- Cash and equivalents $2.4M at Mar 31, 2026, down from $6.0M at Dec 31, 2025; post-quarter capital raises of $1.0M from warrant inducement.
- Israeli Ministry of Health approved Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer; CTA submitted to Germany.
- Phase 2/3 trial initiation remains on track for Q2 2026 with safety run-in of ~18 patients, then randomized cohort of ~166.
- Company believes post-quarter equity transactions restored Nasdaq compliance with $2.5M minimum shareholders' equity requirement.

## SEC filing metadata
- accession: 0001178913-26-002761
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-05-18T12:33:17+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002761/0001178913-26-002761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002761/zk2635360.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-002761
- JSON: https://secwatch.observer/filing/0001178913-26-002761.json
- Plain text: https://secwatch.observer/filing/0001178913-26-002761.txt

## Key facts
- Earnings Releases
  Silexion Therapeutics Corp reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026, was approximately $2.7 million.
  - Period: first quarter ended March 31, 2026
  - Net income: Net loss for the three months ended March 31, 2026, was approximately $2.7 million
  - Result: reported results
  source text: On May 18, 2026, Silexion Therapeutics Corp issued a press release announcing its financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002761/0001178913-26-002761-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.